[Chimeric anti-CD25 monoclonal antibody for treating acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
OBJECTIVE
To investigate the efficacy of chimeric anti-CD(25) monoclonal antibody (basiliximab) on acute graft-versus-host disease (GVHD) in patients following allogeneic hematopoietic stem cell transplantation.


METHODS
Thirty-six patients who were suffered from acute GVHD from March 2005 to July 2007 were studied. All of them were treated with steroid first and got no response, then began basiliximab therapy.


RESULTS
Thirty of 36 patients showed response to basiliximab therapy including 25 complete responses and 5 partial responses. The efficacy was associated with the degree of GVHD and the source of donor.


CONCLUSIONS
Patients suffered from steroid-resistant acute GVHD can be successfully treated with basiliximab.
Wang
Jing-zhi
JZ
Institute of Hematology, People's Hospital, Peking University, Beijing 100044, China.
Liu
Kai-yan
KY
Xu
Lan-ping
LP
Liu
Dai-hong
DH
Chen
Yu-hong
YH
Huang
Xiao-jun
XJ
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006086:Graft vs Host Disease / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D053645:Interleukin-2 Receptor alpha Subunit